
Episode 76
Biotech Hangout
00:00
Merck Keynote 671 Study and Overall Survival in Lung Cancer
Discussion on the Merck Keynote 671 study, focusing on resectable lung cancer at stage 2, 3A, or 3B. The study reveals that giving Keytruda before surgical resection has shown an overall survival advantage, marking a significant development in neo-adjuvant studies with a PD-1 in lung cancer.
Transcript
Play full episode